NCT04566614Completed
Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies
Source: ClinicalTrials.gov · Last updated 6 Apr 2025
Brief summary (registry, in English)
The purpose of this study is to investigate the feasibility of using ctDNA to support cancer diagnosis and risk stratification where invasive aerosol generating testing (and/or tissue biopsy) is challenging due to infection risk, technical impracticalities and resource limitations, such as during the COVID-19 pandemic and the subsequent recovery period.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 128 (actual)
- First submitted
- 2 Jun 2020
- Start date
- 18 Jun 2020
- Primary completion date
- 31 Jul 2023
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- NCT number
- NCT04566614
What you commit to
- Study type: Observational
- Participants enrolled: 128
- From 18 Jun 2020 to the primary completion date, 31 Jul 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously diagnosed invasive or haematological malignancy within the past 3 years
Other illness
- Outcome at the molecular tumour board not supportive of cancer diagnosis (possibly consistent or not consistent)
Who the study is looking for
- Participants aged ≥18 years old
- Patients with suspected malignancies of early stage colorectal cancer (FIT intermediate and high risk), early and late stage pancreatic cancer, biliary tract cancer, gastro-intestinal stromal tumours, lung cancer or bladder cancer, without a definitive histological diagnosis (including those with inconclusive biopsy result) or
- Patients with histological diagnosis of lung cancer without adequate tissue for NHS genomic test directory predictive biomarker testing
- Ability to provide informed consent.
- Patients with performance status suitable for oncological treatments (ECOG performance status 0-2).
- Exclusion criterion:
- Patients with an established histological diagnosis adequate to support standard of care treatment
- PART 2:
- Included in the ACCESS implementation programme
- Has detectable ctDNA on Guardant360© assay
- Discussion at molecular tumour board and central multi-disciplinary meeting confirming ctDNA variant is supportive of diagnosis of PC/BTC (diagnostic or consistent with)
- Performance status suitable for oncological treatment
- Ability to provide informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Marsden Hospital Coordinator of this site? Confirm its status | Sutton | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.